An Open-Label Trial in Genotype 2, 3, 4, 5 and 6 Hepatitis C-Infected Subjects to Evaluate the Antiviral Activity, Safety, Tolerability and Pharmacokinetics of TMC435350 Following 7 Days Once Daily Dosing as Monotherapy.

Trial Profile

An Open-Label Trial in Genotype 2, 3, 4, 5 and 6 Hepatitis C-Infected Subjects to Evaluate the Antiviral Activity, Safety, Tolerability and Pharmacokinetics of TMC435350 Following 7 Days Once Daily Dosing as Monotherapy.

Completed
Phase of Trial: Phase II

Latest Information Update: 26 Sep 2014

At a glance

  • Drugs Simeprevir (Primary)
  • Indications Hepatitis C
  • Focus Therapeutic Use
  • Acronyms OPERA-2
  • Sponsors Janssen R&D Ireland
  • Most Recent Events

    • 01 Oct 2010 According to a Medivir media release, the results of this trial will be presented at the 61st Annual Meeting of the American Association for the Study of Liver Diseases (AASLD).
    • 27 Apr 2010 Additional trial location (Ireland) identified as reported by ClinicalTrials.gov.
    • 12 Dec 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top